epinephrine · Ars Pharms Operation · NDA 214697
Neffy
Earliest generic entry, as listed · earliest of 2 marketed strengths
6 Feb 2039
Blocked by patent: US 10682414, US 11191838, US 11717571, US 11744895, US 11918655, US 12324838.
Listed patents · 8 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10682414 | use U-3979 | 6 Feb 2039 |
| US 11191838 | product, use U-3979 | 6 Feb 2039 |
| US 11717571 | use U-3979 | 6 Feb 2039 |
| US 11744895 | use U-3979 | 6 Feb 2039 |
| US 11918655 | use U-3979 | 6 Feb 2039 |
| US 12324838 | product | 6 Feb 2039 |
| US 10576156 | product | 6 Feb 2038 |
| US 11173209 | use U-3979 | 6 Feb 2038 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 2
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 214697 · 001 · RLD | spray, nasal | 2MG/SPRAY | 6 Feb 2039 |
| 214697 · 002 · RLD | spray, nasal | 1MG/SPRAY | 6 Feb 2039 |